헤파린 : 세계 시장 점유율과 순위, 총판매량 및 수요 예측(2025-2031년)

The global market for Heparin was estimated to be worth US$ 1225 million in 2024 and is forecast to a readjusted size of US$ 2301 million by 2031 with a CAGR of 7.8% during the forecast period 2025-2031.

This report provides a comprehensive assessment of recent tariff adjustments and international strategic countermeasures on Heparin cross-border industrial footprints, capital allocation patterns, regional economic interdependencies, and supply chain reconfigurations.

In 2024, global Heparin production reached approximately 23,498 billion units , with an average global market price of around US$ 52,147 per billion units. Heparin is an anticoagulant (blood thinner) that prevents the formation of blood clots. Heparin is used to treat and prevent blood clots in the veins, arteries, or lung. It is also used before surgery to reduce the risk of blood clots. Most of the Heparin product is existed in a form of Heparin Sodium or Heparin Calcium. In this report, we mainly study the Heparin API.

Global key players of Heparin include Shenzhen Hepalink Pharmaceutical, Yantai Dongcheng Pharmaceutical, Nanjing King-friend Biochemical Pharmaceutical, Pfizer, Hebei Changshan Biochemical Pharmaceutical, etc. The top five manufacturers hold a share about 54%. China is dominating the global Heparin market, has a share over 65% in terms of production. Europe and Asia-Pacific are the two largest market, both having a share about 34%, followed by North America, with a share about 30 percent.

The heparin API market is primarily driven by the rising global prevalence of cardiovascular and thromboembolic diseases, along with increasing surgical procedures. Growing aging populations and higher obesity rates contribute to sustained demand for anticoagulants. Additionally, heparin's use in treating COVID-19-associated thrombotic complications has further propelled market expansion. Pharmaceutical industry advancements in emerging markets (e.g., China and India) and the biopharmaceutical sector's demand for high-quality heparin also fuel market growth.

Key trends in the heparin API market include: 1) a technological shift from animal-sourced heparin (porcine intestinal mucosa extraction) to synthetic alternatives (e.g., low-molecular-weight heparin); 2) stringent regulatory requirements for supply chain traceability and quality control; 3) intensified competition from biosimilars, driving process optimization and cost reduction; and 4) the rise of local pharmaceutical players in emerging markets, diversifying the global heparin supply chain.

This report aims to provide a comprehensive presentation of the global market for Heparin, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Heparin by region & country, by Type, and by Application.

The Heparin market size, estimations, and forecasts are provided in terms of sales volume (billion units) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Heparin.

Market Segmentation

By Company

• Shenzhen Hepalink Pharmaceutical
• Yantai Dongcheng Pharmaceutical
• Pfizer
• Bioiberica
• Changzhou Qianhong Biopharma
• Nanjing King-friend Biochemical Pharmaceutical
• Hebei Changshan Biochemical Pharmaceutical
• Qingdao Jiulong Biopharmaceutical
• Opocrin
• Dongying Tiandong Pharmaceutical
• Aspen Oss
• Yino Pharma
• Nanjing Xinbai Pharmaceutical
• Hubei Enoray Biopharmaceutical
• Cisen Pharmaceutical

Segment by Type

• Heparin Sodium
• Heparin Calcium

Segment by Application

• UFH
• LMWH

By Region

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • South Korea
  • Southeast Asia
  • India
  • Australia
  • Rest of Asia-Pacific
• Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Netherlands
  • Nordic Countries
  • Rest of Europe
• Latin America
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa
  • Turkey
  • Saudi Arabia
  • UAE
  • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size (value, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Heparin manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Sales, revenue of Heparin in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Sales, revenue of Heparin in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

• 1.1 Heparin Product Introduction
• 1.2 Global Heparin Market Size Forecast
  • 1.2.1 Global Heparin Sales Value (2020-2031)
  • 1.2.2 Global Heparin Sales Volume (2020-2031)
  • 1.2.3 Global Heparin Sales Price (2020-2031)
• 1.3 Heparin Market Trends & Drivers
  • 1.3.1 Heparin Industry Trends
  • 1.3.2 Heparin Market Drivers & Opportunity
  • 1.3.3 Heparin Market Challenges
  • 1.3.4 Heparin Market Restraints
• 1.4 Assumptions and Limitations
• 1.5 Study Objectives
• 1.6 Years Considered

2 Competitive Analysis by Company

• 2.1 Global Heparin Players Revenue Ranking (2024)
• 2.2 Global Heparin Revenue by Company (2020-2025)
• 2.3 Global Heparin Players Sales Volume Ranking (2024)
• 2.4 Global Heparin Sales Volume by Company Players (2020-2025)
• 2.5 Global Heparin Average Price by Company (2020-2025)
• 2.6 Key Manufacturers Heparin Manufacturing Base and Headquarters
• 2.7 Key Manufacturers Heparin Product Offered
• 2.8 Key Manufacturers Time to Begin Mass Production of Heparin
• 2.9 Heparin Market Competitive Analysis
  • 2.9.1 Heparin Market Concentration Rate (2020-2025)
  • 2.9.2 Global 5 and 10 Largest Manufacturers by Heparin Revenue in 2024
  • 2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Heparin as of 2024)
• 2.10 Mergers & Acquisitions, Expansion

3 Segmentation by Type

• 3.1 Introduction by Type
  • 3.1.1 Heparin Sodium
  • 3.1.2 Heparin Calcium
• 3.2 Global Heparin Sales Value by Type
  • 3.2.1 Global Heparin Sales Value by Type (2020 VS 2024 VS 2031)
  • 3.2.2 Global Heparin Sales Value, by Type (2020-2031)
  • 3.2.3 Global Heparin Sales Value, by Type (%) (2020-2031)
• 3.3 Global Heparin Sales Volume by Type
  • 3.3.1 Global Heparin Sales Volume by Type (2020 VS 2024 VS 2031)
  • 3.3.2 Global Heparin Sales Volume, by Type (2020-2031)
  • 3.3.3 Global Heparin Sales Volume, by Type (%) (2020-2031)
• 3.4 Global Heparin Average Price by Type (2020-2031)

4 Segmentation by Application

• 4.1 Introduction by Application
  • 4.1.1 UFH
  • 4.1.2 LMWH
• 4.2 Global Heparin Sales Value by Application
  • 4.2.1 Global Heparin Sales Value by Application (2020 VS 2024 VS 2031)
  • 4.2.2 Global Heparin Sales Value, by Application (2020-2031)
  • 4.2.3 Global Heparin Sales Value, by Application (%) (2020-2031)
• 4.3 Global Heparin Sales Volume by Application
  • 4.3.1 Global Heparin Sales Volume by Application (2020 VS 2024 VS 2031)
  • 4.3.2 Global Heparin Sales Volume, by Application (2020-2031)
  • 4.3.3 Global Heparin Sales Volume, by Application (%) (2020-2031)
• 4.4 Global Heparin Average Price by Application (2020-2031)

5 Segmentation by Region

• 5.1 Global Heparin Sales Value by Region
  • 5.1.1 Global Heparin Sales Value by Region: 2020 VS 2024 VS 2031
  • 5.1.2 Global Heparin Sales Value by Region (2020-2025)
  • 5.1.3 Global Heparin Sales Value by Region (2026-2031)
  • 5.1.4 Global Heparin Sales Value by Region (%), (2020-2031)
• 5.2 Global Heparin Sales Volume by Region
  • 5.2.1 Global Heparin Sales Volume by Region: 2020 VS 2024 VS 2031
  • 5.2.2 Global Heparin Sales Volume by Region (2020-2025)
  • 5.2.3 Global Heparin Sales Volume by Region (2026-2031)
  • 5.2.4 Global Heparin Sales Volume by Region (%), (2020-2031)
• 5.3 Global Heparin Average Price by Region (2020-2031)
• 5.4 North America
  • 5.4.1 North America Heparin Sales Value, 2020-2031
  • 5.4.2 North America Heparin Sales Value by Country (%), 2024 VS 2031
• 5.5 Europe
  • 5.5.1 Europe Heparin Sales Value, 2020-2031
  • 5.5.2 Europe Heparin Sales Value by Country (%), 2024 VS 2031
• 5.6 Asia Pacific
  • 5.6.1 Asia Pacific Heparin Sales Value, 2020-2031
  • 5.6.2 Asia Pacific Heparin Sales Value by Region (%), 2024 VS 2031
• 5.7 South America
  • 5.7.1 South America Heparin Sales Value, 2020-2031
  • 5.7.2 South America Heparin Sales Value by Country (%), 2024 VS 2031
• 5.8 Middle East & Africa
  • 5.8.1 Middle East & Africa Heparin Sales Value, 2020-2031
  • 5.8.2 Middle East & Africa Heparin Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

• 6.1 Key Countries/Regions Heparin Sales Value Growth Trends, 2020 VS 2024 VS 2031
• 6.2 Key Countries/Regions Heparin Sales Value and Sales Volume
  • 6.2.1 Key Countries/Regions Heparin Sales Value, 2020-2031
  • 6.2.2 Key Countries/Regions Heparin Sales Volume, 2020-2031
• 6.3 United States
  • 6.3.1 United States Heparin Sales Value, 2020-2031
  • 6.3.2 United States Heparin Sales Value by Type (%), 2024 VS 2031
  • 6.3.3 United States Heparin Sales Value by Application, 2024 VS 2031
• 6.4 Europe
  • 6.4.1 Europe Heparin Sales Value, 2020-2031
  • 6.4.2 Europe Heparin Sales Value by Type (%), 2024 VS 2031
  • 6.4.3 Europe Heparin Sales Value by Application, 2024 VS 2031
• 6.5 China
  • 6.5.1 China Heparin Sales Value, 2020-2031
  • 6.5.2 China Heparin Sales Value by Type (%), 2024 VS 2031
  • 6.5.3 China Heparin Sales Value by Application, 2024 VS 2031
• 6.6 Japan
  • 6.6.1 Japan Heparin Sales Value, 2020-2031
  • 6.6.2 Japan Heparin Sales Value by Type (%), 2024 VS 2031
  • 6.6.3 Japan Heparin Sales Value by Application, 2024 VS 2031
• 6.7 South Korea
  • 6.7.1 South Korea Heparin Sales Value, 2020-2031
  • 6.7.2 South Korea Heparin Sales Value by Type (%), 2024 VS 2031
  • 6.7.3 South Korea Heparin Sales Value by Application, 2024 VS 2031
• 6.8 Southeast Asia
  • 6.8.1 Southeast Asia Heparin Sales Value, 2020-2031
  • 6.8.2 Southeast Asia Heparin Sales Value by Type (%), 2024 VS 2031
  • 6.8.3 Southeast Asia Heparin Sales Value by Application, 2024 VS 2031
• 6.9 India
  • 6.9.1 India Heparin Sales Value, 2020-2031
  • 6.9.2 India Heparin Sales Value by Type (%), 2024 VS 2031
  • 6.9.3 India Heparin Sales Value by Application, 2024 VS 2031

7 Company Profiles

• 7.1 Shenzhen Hepalink Pharmaceutical
  • 7.1.1 Shenzhen Hepalink Pharmaceutical Company Information
  • 7.1.2 Shenzhen Hepalink Pharmaceutical Introduction and Business Overview
  • 7.1.3 Shenzhen Hepalink Pharmaceutical Heparin Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.1.4 Shenzhen Hepalink Pharmaceutical Heparin Product Offerings
  • 7.1.5 Shenzhen Hepalink Pharmaceutical Recent Development
• 7.2 Yantai Dongcheng Pharmaceutical
  • 7.2.1 Yantai Dongcheng Pharmaceutical Company Information
  • 7.2.2 Yantai Dongcheng Pharmaceutical Introduction and Business Overview
  • 7.2.3 Yantai Dongcheng Pharmaceutical Heparin Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.2.4 Yantai Dongcheng Pharmaceutical Heparin Product Offerings
  • 7.2.5 Yantai Dongcheng Pharmaceutical Recent Development
• 7.3 Pfizer
  • 7.3.1 Pfizer Company Information
  • 7.3.2 Pfizer Introduction and Business Overview
  • 7.3.3 Pfizer Heparin Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.3.4 Pfizer Heparin Product Offerings
  • 7.3.5 Pfizer Recent Development
• 7.4 Bioiberica
  • 7.4.1 Bioiberica Company Information
  • 7.4.2 Bioiberica Introduction and Business Overview
  • 7.4.3 Bioiberica Heparin Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.4.4 Bioiberica Heparin Product Offerings
  • 7.4.5 Bioiberica Recent Development
• 7.5 Changzhou Qianhong Biopharma
  • 7.5.1 Changzhou Qianhong Biopharma Company Information
  • 7.5.2 Changzhou Qianhong Biopharma Introduction and Business Overview
  • 7.5.3 Changzhou Qianhong Biopharma Heparin Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.5.4 Changzhou Qianhong Biopharma Heparin Product Offerings
  • 7.5.5 Changzhou Qianhong Biopharma Recent Development
• 7.6 Nanjing King-friend Biochemical Pharmaceutical
  • 7.6.1 Nanjing King-friend Biochemical Pharmaceutical Company Information
  • 7.6.2 Nanjing King-friend Biochemical Pharmaceutical Introduction and Business Overview
  • 7.6.3 Nanjing King-friend Biochemical Pharmaceutical Heparin Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.6.4 Nanjing King-friend Biochemical Pharmaceutical Heparin Product Offerings
  • 7.6.5 Nanjing King-friend Biochemical Pharmaceutical Recent Development
• 7.7 Hebei Changshan Biochemical Pharmaceutical
  • 7.7.1 Hebei Changshan Biochemical Pharmaceutical Company Information
  • 7.7.2 Hebei Changshan Biochemical Pharmaceutical Introduction and Business Overview
  • 7.7.3 Hebei Changshan Biochemical Pharmaceutical Heparin Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.7.4 Hebei Changshan Biochemical Pharmaceutical Heparin Product Offerings
  • 7.7.5 Hebei Changshan Biochemical Pharmaceutical Recent Development
• 7.8 Qingdao Jiulong Biopharmaceutical
  • 7.8.1 Qingdao Jiulong Biopharmaceutical Company Information
  • 7.8.2 Qingdao Jiulong Biopharmaceutical Introduction and Business Overview
  • 7.8.3 Qingdao Jiulong Biopharmaceutical Heparin Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.8.4 Qingdao Jiulong Biopharmaceutical Heparin Product Offerings
  • 7.8.5 Qingdao Jiulong Biopharmaceutical Recent Development
• 7.9 Opocrin
  • 7.9.1 Opocrin Company Information
  • 7.9.2 Opocrin Introduction and Business Overview
  • 7.9.3 Opocrin Heparin Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.9.4 Opocrin Heparin Product Offerings
  • 7.9.5 Opocrin Recent Development
• 7.10 Dongying Tiandong Pharmaceutical
  • 7.10.1 Dongying Tiandong Pharmaceutical Company Information
  • 7.10.2 Dongying Tiandong Pharmaceutical Introduction and Business Overview
  • 7.10.3 Dongying Tiandong Pharmaceutical Heparin Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.10.4 Dongying Tiandong Pharmaceutical Heparin Product Offerings
  • 7.10.5 Dongying Tiandong Pharmaceutical Recent Development
• 7.11 Aspen Oss
  • 7.11.1 Aspen Oss Company Information
  • 7.11.2 Aspen Oss Introduction and Business Overview
  • 7.11.3 Aspen Oss Heparin Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.11.4 Aspen Oss Heparin Product Offerings
  • 7.11.5 Aspen Oss Recent Development
• 7.12 Yino Pharma
  • 7.12.1 Yino Pharma Company Information
  • 7.12.2 Yino Pharma Introduction and Business Overview
  • 7.12.3 Yino Pharma Heparin Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.12.4 Yino Pharma Heparin Product Offerings
  • 7.12.5 Yino Pharma Recent Development
• 7.13 Nanjing Xinbai Pharmaceutical
  • 7.13.1 Nanjing Xinbai Pharmaceutical Company Information
  • 7.13.2 Nanjing Xinbai Pharmaceutical Introduction and Business Overview
  • 7.13.3 Nanjing Xinbai Pharmaceutical Heparin Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.13.4 Nanjing Xinbai Pharmaceutical Heparin Product Offerings
  • 7.13.5 Nanjing Xinbai Pharmaceutical Recent Development
• 7.14 Hubei Enoray Biopharmaceutical
  • 7.14.1 Hubei Enoray Biopharmaceutical Company Information
  • 7.14.2 Hubei Enoray Biopharmaceutical Introduction and Business Overview
  • 7.14.3 Hubei Enoray Biopharmaceutical Heparin Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.14.4 Hubei Enoray Biopharmaceutical Heparin Product Offerings
  • 7.14.5 Hubei Enoray Biopharmaceutical Recent Development
• 7.15 Cisen Pharmaceutical
  • 7.15.1 Cisen Pharmaceutical Company Information
  • 7.15.2 Cisen Pharmaceutical Introduction and Business Overview
  • 7.15.3 Cisen Pharmaceutical Heparin Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.15.4 Cisen Pharmaceutical Heparin Product Offerings
  • 7.15.5 Cisen Pharmaceutical Recent Development

8 Industry Chain Analysis

• 8.1 Heparin Industrial Chain
• 8.2 Heparin Upstream Analysis
  • 8.2.1 Key Raw Materials
  • 8.2.2 Raw Materials Key Suppliers
  • 8.2.3 Manufacturing Cost Structure
• 8.3 Midstream Analysis
• 8.4 Downstream Analysis (Customers Analysis)
• 8.5 Sales Model and Sales Channels
  • 8.5.1 Heparin Sales Model
  • 8.5.2 Sales Channel
  • 8.5.3 Heparin Distributors

9 Research Findings and Conclusion

10 Appendix

• 10.1 Research Methodology
  • 10.1.1 Methodology/Research Approach
    • 10.1.1.1 Research Programs/Design
    • 10.1.1.2 Market Size Estimation
    • 10.1.1.3 Market Breakdown and Data Triangulation
  • 10.1.2 Data Source
    • 10.1.2.1 Secondary Sources
    • 10.1.2.2 Primary Sources
• 10.2 Author Details
• 10.3 Disclaimer